Opioid agonist therapy should be normalised as a routine part of opioid dependence treatment
Australia faces a pharmaceutical opioid crisis.1 Rates of prescribing, morbidity and mortality have dramatically increased since 1990.1 Fifty‐six percent of unintentional opioid deaths now involve pharmaceutical opioids (as either sole drug or polydrug overdose), compared with 45% of deaths involving heroin and 23% involving methadone.2 Despite this, methadone carries considerable stigma and misconceptions among clinicians and community members.3 The cost of private prescriptions, provider unfamiliarity with the medication and clinician reluctance to manage patients with illicit and prescription opioid use disorder are common barriers to opioid agonist therapy (OAT).3
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Australian Institute of Health and Welfare. Alcohol, tobacco and other drugs in Australia [web report]. Canberra: AIHW, 2021. https://www.aihw.gov.au/reports/alcohol/alcohol-tobacco-other-drugs-australia/contents/introduction (viewed May 2021).
- 2. Penington Institute. Australia’s annual overdose report 2020. Melbourne: Penington Institute, 2020. https://www.penington.org.au/wp-content/uploads/Australias-Annual-Overdose-Report-2020.pdf (viewed Dec 2020).
- 3. Hotham L, Roche A, Skinner N. Training general practitioners to prescribe methadone (and other pharmacotherapies): outcomes and uptake in four jurisdictions. Adelaide: National Centre for Education and Training on Addiction, Flinders University, 2003. http://nceta.flinders.edu.au/files/6712/5548/2798/EN219.pdf (viewed Sept 2020).
- 4. McDonough M. Opioid treatment of opioid addiction. Aust Prescr 2013; 36: 83–87.
- 5. Frieden TR, Houry D. Reducing the risks of relief—the CDC opioid-prescribing guideline. N Engl J Med 2016; 374: 1501–1504.
- 6. Fischer B, Jones W, Tyndall M, et al. Correlations between opioid mortality increases related to illicit/synthetic opioids and reductions of medical opioid dispensing - exploratory analyses from Canada. BMC Public Health 2020; 20: 143.
- 7. Therapeutic Goods Administration. Consultation: Prescription strong (Schedule 8) opioid use and misuse in Australia – options for a regulatory response. Canberra: Commonwealth of Australia, 2018. https://www.tga.gov.au/consultation/consultation-prescription-strong-schedule-8-opioid-use-and-misuse-australia-options-regulatory-response (viewed Oct 2020).
- 8. Fatseas M, Auriacombe M. Why buprenorphine is so successful in treating opiate addiction in France. Curr Psychiatry Rep 2007; 9: 358–364.
- 9. Australian Institute of Health and Welfare. National opioid pharmacotherapy statistics annual data collection (Cat. No. PHE 266) [web report]. https://www.aihw.gov.au/reports/alcohol-other-drug-treatment-services/national-opioid-pharmacotherapy-statistics/contents/summary (viewed May 2021)
- 10. Australian Health Practitioner Regulation Authority. Medical Board of Australia registrant data. February 2021. https://www.medicalboard.gov.au/News/Statistics.aspx (viewed May 2021)
No relevant disclosures.